Key result
At 20 months of age, female mice homozygous for the Fhl1 p.W122S mutation developed cardiomyopathy with significantly lower fractional shortening (22.4% vs 31.1%, P<0.01) compared to wild-type mice.
The Fhl1 mutant female mouse model develops late-onset cardiomyopathy associated with integrin signaling pathway dysregulation, providing the first mouse model for FHL1-related cardiomyopathy.
Cautions against extrapolating mouse data to patients; leaves open whether FHL1 mutations drive human cardiomyopathy.
X-linked scapuloperoneal myopathy (X-SM), one of Four-and-a-half LIM 1 (FHL1) related diseases, is an adult-onset slowly progressive myopathy, often associated with cardiomyopathy. We previously generated a knock-in mouse model that has the same mutation (c.365 G > C, p.W122S) as human X-SM patients. The mutant male mouse developed late-onset slowly progressive myopathy without cardiomyopathy. In this study, we observed that heterozygous (Het) and homozygous (Homo) female mice did not show alterations of skeletal muscle function or histology. In contrast, 20-month-old mutant female mice showed signs of cardiomyopathy on echocardiograms with increased systolic diameter [wild-type (WT): 2.74 ± 0.22 mm, mean ± standard deviation (SD); Het: 3.13 ± 0.11 mm, P < 0.01; Homo: 3.08 ± 0.37 mm, P < 0.05) and lower fractional shortening (WT: 31.1 ± 4.4%, mean ± SD; Het: 22.7 ± 2.5%, P < 0.01; Homo: 22.4 ± 6.9%, P < 0.01]. Histological analysis of cardiac muscle revealed frequent extraordinarily large rectangular nuclei in mutant female mice that were also observed in human cardiac muscle from X-SM patients. Western blot demonstrated decreased Fhl1 protein levels in cardiac muscle, but not in skeletal muscle, of Homo mutant female mice. Proteomic analysis of cardiac muscle from 20-month-old Homo mutant female mice indicated abnormalities of the integrin signaling pathway (ISP) in association with cardiac dysfunction. The ISP dysregulation was further supported by altered levels of a subunit of the ISP downstream effectors Arpc1a in Fhl1 mutant mice and ARPC1A in X-SM patient muscles. This study reveals the first mouse model of FHL1-related cardiomyopathy and implicates ISP dysregulation in the pathogenesis of FHL1 myopathy.
No takes yet. Share an insight, caveat, or question.
Kubota et al. (2018) studied FHL1-related cardiomyopathy. Fhl1 p.W122S mutation vs. Wild-type was evaluated on Fractional shortening at 20 months (p=<0.01). At 20 months of age, female mice homozygous for the Fhl1 p.W122S mutation developed cardiomyopathy with significantly lower fractional shortening (22.4% vs 31.1%, P<0.01) compared to wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: